Most Read Articles
Roshini Claire Anthony, 4 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 5 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, 3 days ago
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Sex-specific thresholds of high-sensitivity troponin identify more women with myocardial injury

23 Oct 2019

Implementing a high-sensitivity cardiac troponin I assay with sex-specific diagnostic thresholds results in identifying five times more women than men with myocardial injury, reports a study.

“Despite this increase, women received approximately one-half the number of treatments for coronary artery disease as men, and outcomes were not improved,” the investigators said.

To evaluate the impact of using a high-sensitivity cardiac troponin I assay with sex-specific thresholds for myocardial infarction (MI), the investigators enrolled consecutive patients with suspected acute coronary syndrome in a stepped-wedge, cluster-randomized controlled trial across 10 hospitals.

Myocardial injury was defined as high-sensitivity cardiac troponin I concentration >99th centile of 16 ng/l in women and 34 ng/l in men. Recurrent MI or cardiovascular (CV) death at 1 year was the primary outcome.

Overall, 48,282 patients (47 percent women) were eligible for the study. Use of the high-sensitivity cardiac troponin I assay with sex-specific thresholds led to a 42-percent increase in myocardial injury in women and a 6-percent risk in men.

Following this implementation, women with myocardial injury were still less likely than men to undergo coronary revascularization (15 percent vs 34 percent) and to receive treatment such as dual antiplatelet (26 percent vs 43 percent), statin (16 percent vs 26 percent) or other preventive therapies (p-all<0.001).

Eighteen percent and 17 percent of women with myocardial injury experienced recurrent MI or CV death 1 year before and after implementation, respectively (adjusted hazard ratio [aHR], 1.11, 95 percent CI, 0.92–1.33), as compared with 18 percent and 15 percent of men (aHR, 0.85, 0.71–1.01).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 5 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, 3 days ago
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).